Industry Overview - The drug and biotech industry faced challenges in the past months due to disappointing Q3 sales, guidance cuts, and pipeline setbacks, but is expected to recover in 2025 [2] - Innovation in areas like rare diseases, oncology, obesity, immunology, and neuroscience is driving investor interest, with R&D remaining a key focus in 2025 [3] - The Zacks Large Cap Pharmaceuticals industry includes global companies developing drugs for therapeutic areas like neuroscience, cardiovascular, rare diseases, immunology, and oncology, with some also involved in vaccines, animal health, and medical devices [5] - Large drugmakers invest heavily in product pipelines and line extensions, with continuous innovation and M&A activity being defining characteristics [6] Key Drivers and Challenges - Innovation and pipeline success are critical for top-line growth, with pharma companies spending a significant portion of revenues on R&D [7] - Aggressive M&A activity is a key feature, with large companies acquiring smaller biotech firms to build pipelines, particularly in oncology, rare diseases, and cell and gene therapy [8][9] - Recent major M&A deals include Eli Lilly's buyout of Morphic, Vertex's acquisition of Alpine Immune Sciences, and Novo Nordisk's purchase of Catalent [10] - Pipeline setbacks, regulatory delays, pricing pressure, generic competition, and macroeconomic uncertainty are significant headwinds for the industry [11][12] Industry Performance and Valuation - The Zacks Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 146, placing it in the bottom 41% of Zacks industries [14] - The industry has outperformed the Zacks Medical Sector but underperformed the S&P 500, with a 1.2% decline over the past year compared to the S&P 500's 26.2% rise [15] - The industry's forward 12-month P/E ratio is 18.64X, lower than the S&P 500's 25.08X and the Zacks Medical Sector's 25.47X [16] Key Companies to Watch - **J&J**: Diversified business model with strong growth in the Innovative Medicines segment, expected to exceed $57 billion in sales in 2025 [17][18] - **Pfizer**: Strengthened oncology position with Seagen acquisition, expects operational growth driven by new products and cost cuts of at least $5.5 billion [21][22][23] - **AbbVie**: Successfully navigating Humira's loss of exclusivity with new immunology drugs Skyrizi and Rinvoq, expects mid-single-digit revenue growth in 2025 [24][25][26] - **Eli Lilly**: Strong performance from tirzepatide medicines Mounjaro and Zepbound, with demand expected to drive revenue growth in 2025 [28][29][30][31] - **AstraZeneca**: Diversified portfolio with 12 blockbuster drugs, expects industry-leading top-line growth and $80 billion in revenues by 2030 [33][34][35]

One of the highest achievements a dividend growth stock can attain is the status of a Dividend King. To reach this milestone, a company must increase its annual dividend payout for 50 consecutive years. That is not an easy feat toI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forwa ...

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios. Predominantly utilized before and after surgery, these drugs are pivotal in managing the disease. Significant research efforts are focused on targeted therapies tailored to specific breast cancer types, particularly those characterized by overexpression of human epidermal grow ...

AbbVie (ABBV) closed at $180 in the latest trading session, marking a +0.9% move from the prior day. The stock lagged the S&P 500's daily gain of 1.1%. On the other hand, the Dow registered a gain of 0.91%, and the technology-centric Nasdaq increased by 1.35%.Coming into today, shares of the drugmaker had gained 0.75% in the past month. In that same time, the Medical sector lost 3.78%, while the S&P 500 gained 0.22%.Market participants will be closely following the financial results of AbbVie in its upcomin ...

The world has gotten even more interesting since Part I was published in mid-December. Mystery drones are over New Jersey, the Federal Reserve is walking back the number of rate cuts in 2025, and Quantum Stocks are doing this:If you are a medium to long-term investor looking for an analysis of equities focused on cash flow, growth, and other critical metrics from a financial professional who knows financial statements inside and out, consider giving me a follow.While I am Tech-focused, I have a diversified ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (ABBV 2.37%) is a powerhouse big pharma that has a lot of upside to offer to investors.While there's no guarantee the next three years of the company's life will outperform the market, there's a solid thesis for why it's not improbable. Here's what you need to know about this stock to decide whether you want to own it.The medium-term picture looks good hereAbbVie is notable among the ...

AbbVie (ABBV 2.37%) and Amgen (AMGN 0.84%) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their recent setbacks, these healthcare giants remain attractive income stocks, especially for investors willing to be patient. Here's why.1. AbbVieSometimes acquisitions create value for all those involved. Sometimes they don' ...

Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called "Santa Claus rallies" can occur near the end of the year.Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (ABBV 2.37%), Novo Nordisk (NVO -17.83%), and Vertex Pharmaceuticals (VRTX 0.16%).AbbVie's stock is a bargain buy for long-t ...

What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing. This well-established investment style can hardly compete with newer trends in terms of pure excitement. However, investing in strong dividend stocks remains an excellent way to beat the market over the long run.Let's consider two income-fo ...

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals industry rose 19.3% in the first half of 2024. However, there was a major downturn in the second half due to overall disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services ...